trending Market Intelligence /marketintelligence/en/news-insights/trending/E2sk9kbrMZHxt_H2-TQjIw2 content esgSubNav
In This List

Regen BioPharma seeking patent protection for T-cell tumor treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Regen BioPharma seeking patent protection for T-cell tumor treatment

Regen BioPharma Inc. is seeking U.S. patent protection for a method to use T cells when treating solid tumors.

The company filed a utility patent application with the U.S. Patents and Trademark Office for killing solid tumors using NR2F6-silenced CAR T cells.

"By activating the adaptive arm of the immune system, in the form of NR2F6-silenced T cells, we anticipate achieving synergistic effects in killing of solid tumors, something which has not been observed in previous CAR-T approaches," Regen BioPharma President and Chief Scientific Officer Harry Lander said.